Skip to main content
Fig. 4 | Military Medical Research

Fig. 4

From: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma

Fig. 4

Immunotherapy of advanced HCC using icaritin (a) or icaritin-based nanomedicines (b). Clinically approved nanocarriers (e.g., polymeric conjugates, micelles and liposomes) can be used to deliver icaritin in clinical practice. Compared with free icaritin, icaritin-based nanomedicines display augmented targeted delivery in vivo, resulting in improved therapeutic efficacy for immunotherapy of advanced HCC. Part of this figure was created partially utilizing the templates on https://smart.servier.com/ as a reference. HCC hepatocellular carcinoma

Back to article page